Looking at the 6 month trend in Sorrento after its early year uptrend, the company has released back to back catalyst. However, FDA approval has been the majority in its probability to be valued. The gann square is showing no resistance as both horizontal lines since July have not crossed 50%, they are both currently within 12%, which states full support on its next leg up. Considering all the acquisitions made these year, including the 25% stake $SRNE has in Celularity, it is not unlikely a loss in EPS may be obvious. However, $SRNE has consistently grown yoy and a surprise earnings beat is also likely as they also licensed distribution for Dyactic. Sounds like alot, it is, $SRNE has worked around the clock to develop 74 patents, and the list continues to grow. Expect the unexpected from $SRNE as they are leading the way to becoming the Pfizer and Glaxosmithkline.